DFD 05Alternative Names: DFD05
Latest Information Update: 23 Aug 2016
At a glance
- Originator Promius Pharma
- Class Antivirals; Skin disorder therapies
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Warts
Most Recent Events
- 01 Aug 2016 Promius Pharma completes phase-II clinical trials in Warts in USA (Topical) (NCT02798419)
- 01 Jan 2016 Phase-II clinical trials in Warts in USA (Topical)